Cancer clinical trials in the region Hauts-de-France
334 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Colon cancer
Rectal cancer
Pancreas cancer
Stomach and esophageal cancer
#NCT06937905
#2024-515948-23-00
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
42 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT07357727
#2025-523555-66-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis
Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required DIPSS scores
Intermediate-1
Intermediate-2
High
Excluded previous treatments
Targeted therapy
Allogeneic stem cell transplant
12 recruiting sites
Novartis Pharmaceuticals
Phase 3
Skin cancer
#NCT06264180
Required histologic types
Melanoma
Required histologic sub types
Nodular melanoma
Lentigo maligna melanoma
Superficial spreading melanoma
Acral lentiginous melanoma
Achromic melanoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
BRAF
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Replimune
Phase 3
Stomach and esophageal cancer
#NCT06644781
#2023-509630-19-00
Required histologic types
Esophagus
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
18 recruiting sites
Daiichi Sankyo
Phase 3
Prostate cancer
#NCT06136650
#2023-504957-11-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Internal Vectorised Radiotherapy (IVR)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Internal Vectorised Radiotherapy (IVR)
10 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Chronic myeloid leukemia (CML)
#NCT06423911
#2024-511495-32-00
Partie B (Mutation T315I)
Required disease stage
Chronic phase
Required genetic anomalies
T315I
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Ascentage Pharma Group Inc.
Phase 3
Chronic myeloid leukemia (CML)
#NCT06423911
#2024-511495-32-00
Partie A (Non-T315I)
Required disease stage
Chronic phase
Required number of previous lines of therapy
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded genetic anomalies
T315I
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Ascentage Pharma Group Inc.
Phase 3
Colon cancer
Rectal cancer
#NCT06501482
#2023-504831-42-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Surgery
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 3
Colon cancer
Rectal cancer
#NCT06107920
#2024-516456-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Chemotherapy
Radiotherapy
28 recruiting sites
Hôpital universitaire de Rouen
Phase 3
Lung cancer
#NCT07218146
#2025-522818-23-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at localized stage
Chemotherapy
Bispecific T-cell engager antibodies
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
Bispecific T-cell engager antibodies
15 recruiting sites
Zai Lab (Shanghai) Co., Ltd